Imperagen

Imperagen, a Manchester-based biotech firm that employs AI and quantum physics to enhance enzyme engineering, has successfully concluded a £5 million seed funding round.

Summary of transaction details:

• Value: £5 million
• Sector: Healthcare & Biotech (Enzyme Engineering, AI-native DeepTech)
• Advisor: Not disclosed
• Key Entities: Target: Imperagen; Lead Investor: PXN Ventures; Participating Investors: IQ Capital, Northern Gritstone
• Location: Manchester, UK (Target Company)

Note: This funding injection will primarily be used to accelerate Imperagen's core R&D platform, scale its wet lab operations, expand its AI team, and bolster its go-to-market function across pharmaceuticals, life sciences, personal care, and sustainable chemical sectors. The investment underscores confidence in AI-driven deep tech solutions for improving industrial processes.